Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy.
A patient with acute myeloblastic leukemia received high-dose busulfan (1 mg/kg by mouth every 6 h for 4 days) as myelo-ablative therapy for autologous bone marrow transplantation. Rapid entry of busulfan into the cerebrospinal fluid (CSF) was observed. Plasma and CSF concentrations of busulfan were comparable during the 4 days of treatment. The elimination half-lives of busulfan in plasma and CSF were 2.6 h and 2.8 h respectively during the first 12 h after the last dose.
Hassan
M
M
Karolinska Pharmacy, Stockholm, Sweden.
Ehrsson
H
H
Smedmyr
B
B
Tötterman
T
T
Wallin
I
I
Oberg
G
G
Simonsson
B
B
D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000134:cerebrospinal fluid / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary; D011300:Preoperative Care
D002066:Busulfan